Great Provenge Patient Videos

Quote
Anonymous said:
Give Mr. Angry, our CFO a break.

Under the company's Pump & Dump leadership, we've lost $1.7B and owe $650M, but we've got cash for the payroll for about 2 years.

It's working for heaven's sake.

Anyone who questions the company's profitability needs look no further than the posts about Gold and Hamm. This company has made them a lot of money!

What could be wrong with a company that has the first drug that cures cancer and has made two great men like this fabulously wealthy?

Yours Truly,
The Bulgarian Ambassador to D'Enron
Click to expand...

That brought a tear to my eye!!
 






The liar here is you little r***** and you alone Sad that you can not even read a simple balance sheet.

"If Dendreon sold all of its assets and paid all of its debt do you know what would be left? Thats right. A deficit of 1.7 billion."

"The equity section of a balance is the cumulative amount of earnings a company has earned over its existence."

"Additional Paid in capital is NOT an important indication of solvency because it only indicates how much investors paid over par for the stock."

These are the words of an idiot and quess who wrote them, well you did.. Keep spinning you moron.
 






Listen man, I am not here to lie and deceive like you are.

I am sorry that you get caught up on semantics to complicate the picture for anyone else reading this board.

In accounting circles, shareholder capital is not true equity. Retained earnings is the true equity of a company. Retained earnings is what a company has made or lost since its inception. Shareholder capital is what people have paid over par for the stock. It has nothing to do with earnings or predicting the success of a company. The only thing that shareholder capital can tell anyone in DNDN's case is how long they can continue to lose money. Yes, shareholder capital is keeping them solvent because in the event of bankruptcy they can pay all their obligations. I never said they are insolvent.

Because a balance sheet happens to call the sum of shareholder capital and retained earnings total equity, I apologize for not pointing this distinction out to you. Most people understand it, but since you want to continue lying and deceiving, I should have explained this distinction.

As losses keep mounting quarter over quarter and 500M is a farsical break even number, negative retained earnings will continue to increase. Yes, the shareholder capital and their cash buys time for them. The only things left before either a dilution, a bond offering, bankruptcy or a sale is the remaining cash and the positive 200M difference between shareholder capital and negative retained earnings. DNDN would have to leave a buffer. They can't drain it all before either a dilution, bond offering sale or bankruptcy.

D'Enron is in huge financial peril according to their balance sheet and what we know about the cash burn and what we dont know about future income.

That is why back in January, a publication listed D'Enron as the number 1 company at risk for bankruptcy. Schiffman's response was weak at best. He mentioned the cash and he mentioned revenue growth. What he failed to mention is income. It seems no one at D'Enron ever seems to address income.

Revenues are irrelevant if you have a CFO who doesn't seem to be cognizant about out of control expenses. Revenues are irrelevant when you have a HR guy who is making the most money of any HR guy in the country. A recent college grad at a 50k salary would have done better than that loser. Revenues are irrelevant when you continue to fund a plant that is not needed. Revenues are irrelevant when you continue to pay the legal bills of a criminal on the BOD. Revenues are irrelevant when you have paid 100's of millions to a criminal management. Revenues are irrelevant when margins are so slim on a 1 product company.

In politics, it was once said "It's the economy, stupid"

D'Enron doesn't understand "It's income stupid" and there isnt much time left. The balance sheet is illustrative of that.
 






"In accounting circles, shareholder capital is not true equity. Retained earnings is the true equity of a company."

You are a fucking ignorant moron. Dig deeper idiot. What is in peril is your sanity.
 






Anonymous said:
"In accounting circles, shareholder capital is not true equity. Retained earnings is the true equity of a company."

You are a fucking ignorant moron. Dig deeper idiot. What is in peril is your sanity.
Click to expand...

Cafe Pharma, why do you let that poster use that kind of abusive language to someone who is trying to explain something that he wants to continue misleading people about by painting DNDN's finances as rosy and fine in the face of continued losses and no clear sign of when and how they will earn their first dollar of income.

Dendreons buffer of cash and 200M of paid in capital over their deficit considering their burn rate and no earnings in site indicates they are in a very perilous situation. I understand that someone higher up at DNDN may be coaching him on his responses because there would be no other reason for hims to spew such anger and hatred, but is there any way you can tell them to lighten up on the curses and anger?

I have done nothing but try to explain simple accounting concepts to him and whoever is coaching him and his abusive responses and foul language should be a violation of TOS.

Thank you.
 






Post 64, is there anything else wrong in post 63. You mentioned the one definition the poster
didn't have right. The points of the post are accurate if someone does not think there will be earnings in the near future and there is a major case for that.
 






Yes many things wrong - The poster overuns a thread about prostate cancer victims experience with provenge videos with a completely wrong multi-page rant on accounting. He should be completely ashamed of himself. But in reality he could care less about the patients.

Simple fact is that Dendreon has several years of cash available even at current cash burn rates. The company has managed to cut its cash burn rate in half over this past year. The cash burn rate will continue to imrove in comming quarters. And finally the person posting these long long mult-page rants should committed to a mental institution or placed in jail for libeling 1,500 hardworking Dendreon employees.
 






Go back to post #2 and you will see the mentally ill rants of an asshole. The original post concerned videos of cancer patients describing their experience. This sick poster goes on a rant about Gold. Truly pathetic.
 






Anonymous said:
But in reality he could care less about the patients.
Click to expand...

Simple fact is that the MG's failed choice based on greed of going it alone made this company into a train wreck. This criminal currently on the board was so greedy that he put his own financial interests before cancer patients. Talk about not caring about cancer patients.
 






Provenge is a minor miracle. Cheers to those of us in the labs who did this!

But, the company is no longer a business and it's flailing are keeping it from gettting to patients where it would save lives.

The upper management is curled into a ball waiting indictments.

The sales force has been structured so the people can't make money and they leave.

Every quarter, the fat in general and admin increases (nothing person fat man).

Currently, sales are ~$80 and loses are $90M (sum has been the same for the last 5 qtrs if you back out the IP sale) Evey qtr, the non factory general/admin expenses increase $5M.
Even if it didn't cost a dime to make more product, they need revenue of 4x(80+90) or $680M to break even. With the cost of the extra goods and continued fattening of corporate, I'm guessing it will take sales of nearly $1B for this company to break even.

Such sales are a long way off when your upper management can't focus on anything but legal issues and you can't figure out how to keep a sales force in place and what to do with them.

The place had such promise before the pump and dumpers put them into a state where they can no longer operate as a business. A deep housecleaning would have saved them a year ago. They just don't have it in them to do it now.

Provenge is a great product, the patient videos are right. But, it's nearly irrelevant to the company future.

As one poster said here, liquidation may be the only way that D'Enron saves lives.
 






The cash burn rate has been nearly cut in half over the last 3 quarters. COGS efficiency through automation will happen. The Company is on a path to future profits. To say that $1 billion in sales is requiried to turn a profit are the words of a fool. The best thing that could happen to Dendreon is if the last poster liquidated himself.
 






The above 2 posts were copy and pasted from another thread. Repeating actions over and over are an indication of insanity.

Go back to post #2 and you will see the mentally ill rants of this sick poster. The original post concerned videos of cancer patients describing their experience. This sick poster goes on a rant about Gold. Truly pathetic.

The best thing that could happen to cancer patients is if this poster liquidated himself.
 






Anonymous said:
The cash burn rate has been nearly cut in half over the last 3 quarters. COGS efficiency through automation will happen. The Company is on a path to future profits. To say that $1 billion in sales is requiried to turn a profit are the words of a fool. The best thing that could happen to Dendreon is if the last poster liquidated himself.
Click to expand...

RBC Capital Negative on Dendreon (DNDN) Ahead of Q2 Results

RBC Capital issued some cautious comments on Dendreon (NASDAQ: DNDN) ahead of second quarter results. The firm expects Provenge will likely miss Q2 sales estimates and said the company should close its Atlanta operations to cut expenses.

Off label use of J&J's (NYSE: JNJ) Zytiga will hurt Provenge sales, the firm said.

RBC maintained a Sector Perform rating and cut their price target from $10.00 to $8.50.

Dendreon is scheduled to report results on Monday, July 30, 2012, after the market closes.
 


















Anonymous said:
The analyst is calling for an over 30% share price increase over the next year. Great news.
Click to expand...

Agree it is great news for those who understand that $6.50 is the correct valuation. Stock prices are forward looking and the market is saying it is a $6.50 stock. There is a really foolish person posting on this board (a 1 man pr team seemingly sent here to do damage control for an organization that is being sued and is under federal investigation) who seems to think Provenge will be a major seller, and has a great management team. If that poster's expectations is $8 in a year then great but I think he thinks he is smarter than the market and he sees something that no one else sees. If what that poster says is true this will be well more than a $20 dollar stock and that will never happen because DNDN will never earn a dime. Selling the company is their only option.
 






Provenge is a great seller. Provenge is among the top 10 oncology drug launches of all time. Dendreon with new management in place and a great product will move on to great success. The fool here is you.
 






Anonymous said:
Provenge is a great seller. Provenge is among the top 10 oncology drug launches of all time. Dendreon with new management in place and a great product will move on to great success. The fool here is you.
Click to expand...

Most important evaluation of a company is income and the potential to earn income. Even if your false pumping saying Provenge is a great seller was true, D'Enron can not make INCOME from it. Provenge while it may be a good product at most it is a niche product and will never be a "great seller" as you continue to lie, mislead and pump. As a niche product it may have some value to BP at some point. D'Enrons ONLY chance to do the best thing for cancer patients will be to get the product to BP where there is scale, competence and big marketing budgets and expertise. D'Enron has to know this. A sale has to be in the next few months because the alternative of liquidation or bankruptcy is an awful scenario for cancer patients. I believe JJ cares about cancer patients and knows what he has to do which is selling the company. His predesessor only cared about lining his pockets and that is why we did not partner or sell a year ago.
 






The potential to earn income is great. This is why Dendreon (only a childish idiot would call the company "D'Enron" and is an insult to the 1,500 hard working people of Dendreon) has managed to recently attract top management and marketing talent from Amgen, Lilly, Sanofi, etc.

Provenge is among the top 10 oncology drug launches of all time and you can not change that with your lies.

You should be ashamed of yourself.
 






You should be ashamed of your misrepresetations. 10th highest revenues of an oncology launch only says something about revenues. We know about the 228M revenues in 2011. The stock still sits at $6.

Any of the first 9 that are still in business who didn't partner or sell had a viable business model and not the COGS and wasted expenses like the highest paid HR guy in the country.

Delve deeper into the other 9 companies. See how many didnt partner or sell. Look at the COGS and business model of the 2 or 3 who may have not sold or partnered. You are a joke and you are misrepresenting by not giving a full story/
 






Top Bottom
Back
Quote